Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,376.86
(
-0.43%
)
US TECH 100
28,086.18
(
-0.96%
)
Dow Jones
49,556.41
(
0.06%
)
Brent Oil
108.70
(
1.14%
)
Bitcoin
76,271.62
(
-1.47%
)
News Focus
News Focus
Post# of 257581
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 88680

Friday, 02/18/2011 1:19:10 PM

Friday, February 18, 2011 1:19:10 PM

Post# of 257581
CHMP approves NVS’ Rasilamlo (Rasilez+Amlodipine) for hypertension:

http://www.reuters.com/article/2011/02/18/norvartis-idUSLDE71H1ER20110218

In the US, this product was approved in Aug 2010 (#msg-53782319) and is called Tekamlo (Tekturna+Amlodipine). A 3-in-1 variation with HCTZ added was approved in Dec 2010 (#msg-58062858) and is called Amturnide (Amlodipine+Tekturna+Hydrochlorothiazide).

Standalone sales of Tekturna/Rasilez have been disappointing; maybe these combination products will be material contributors.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today